Innovations in Big Data will have a lasting impact on care and present an opportunity for U.S. pharmaceutical companies, writes Nobuko Kobayashi.
As with any modern social infrastructure in Japan, Japanese healthcare is a legacy from the high growth economic era post-WWII. On the brigOriginal Article
